trending Market Intelligence /marketintelligence/en/news-insights/trending/61xwlchhpupu2uzely0nlq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Constellation Pharmaceuticals elects 2 directors to board

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Constellation Pharmaceuticals elects 2 directors to board

Constellation Pharmaceuticals Inc. said its board elected Elizabeth Trehu and Steven Hoerter as directors.

Trehu, who has 16 years of management experience at several biopharmaceutical companies, is currently the chief medical officer of Jounce Therapeutics Inc.

Hoerter is the chief commercial officer of Agios Pharmaceuticals Inc. where he built and leads the team responsible for the commercialization of the company's portfolio of medicines for cancer and rare genetic diseases.

The appointees "bring considerable experience working in the disease areas of myelofibrosis and prostate cancer that is directly relevant to Constellation’s clinical programs," Constellation Pharmaceuticals' President and CEO Jigar Raythatha said in a statement.

Constellation is advancing two lead clinical programs, one for CPI-1205 to treat a type of prostate cancer as well as solid tumors, and another for CPI-0610 — a potential treatment for myelofibrosis.